Zobrazeno 1 - 10
of 244
pro vyhledávání: '"Emanuela Palmerini"'
Publikováno v:
Oncology and Therapy, Vol 12, Iss 4, Pp 833-841 (2024)
Abstract Background Tenosynovial giant cell tumor (TGCT) is a rare, locally aggressive tumor of the joints, bursa, and tendon sheath that can cause considerable pain and substantial morbidity. Although surgery is the primary treatment for patients wi
Externí odkaz:
https://doaj.org/article/aa59370e0c1c48728d6fd4684bd61877
Autor:
Sandro Pasquali, Viviana Vallacchi, Luca Lalli, Paola Collini, Marta Barisella, Cleofe Romagosa, Silvia Bague, Jean Michel Coindre, Angelo Paolo Dei Tos, Emanuela Palmerini, Vittorio Quagliuolo, Javier Martin-Broto, Antonio Lopez-Pousa, Giovanni Grignani, Jean-Yves Blay, Robert Diaz Beveridge, Elena Casiraghi, Silvia Brich, Salvatore Lorenzo Renne, Laura Bergamaschi, Barbara Vergani, Marta Sbaraglia, Paolo Giovanni Casali, Licia Rivoltini, Silvia Stacchiotti, Alessandro Gronchi
Publikováno v:
EBioMedicine, Vol 106, Iss , Pp 105220- (2024)
Summary: Background: Anthracycline-based neoadjuvant chemotherapy (NAC) may modify tumour immune infiltrate. This study characterized immune infiltrate spatial distribution after NAC in primary high-risk soft tissue sarcomas (STS) and investigate ass
Externí odkaz:
https://doaj.org/article/9c4dae51bf654791ba8894a2a7b975fd
Autor:
Paolo Spinnato, Nicolas Papalexis, Marco Colangeli, Marco Miceli, Amandine Crombé, Anna Parmeggiani, Emanuela Palmerini, Alberto Righi, Giuseppe Bianchi
Publikováno v:
Clinics and Practice, Vol 13, Iss 6, Pp 1369-1382 (2023)
Alveolar soft part sarcoma (ASPS) is an extremely rare and aggressive soft-tissue sarcoma (STS) subtype with poor prognosis and limited response to radiation therapy and chemotherapy. Prompt recognition and referral to sarcoma centers for appropriate
Externí odkaz:
https://doaj.org/article/eff713ba9bf24424b9983b519075cb3f
Autor:
Roelof van Ewijk, Nikolas Herold, Fredrik Baecklund, Daniel Baumhoer, Kjetil Boye, Nathalie Gaspar, Semi B. Harrabi, Lianne M. Haveman, Stefanie Hecker-Nolting, Laura Hiemcke-Jiwa, Valentine Martin, Cristina Mata Fernández, Emanuela Palmerini, Michiel A.J. van de Sande, Sandra J. Strauss, Stefan S. Bielack, Leo Kager
Publikováno v:
EJC Paediatric Oncology, Vol 2, Iss , Pp 100029- (2023)
Osteosarcoma is a challenging disease requiring multidisciplinary management in expert centers for optimal outcome. There are no current international protocols or guidelines specific for pediatric and adolescent osteosarcoma. The European Standard C
Externí odkaz:
https://doaj.org/article/2abd60180a884349b219cab8a21b4ec8
Autor:
Maren Høland, Kaja C.G. Berg, Ina A. Eilertsen, Bodil Bjerkehagen, Matthias Kolberg, Kjetil Boye, Ole Christian Lingjærde, Tormod K. Guren, Nils Mandahl, Eva van den Berg, Emanuela Palmerini, Sigbjørn Smeland, Piero Picci, Fredrik Mertens, Anita Sveen, Ragnhild A. Lothe
Publikováno v:
EBioMedicine, Vol 97, Iss , Pp 104829- (2023)
Summary: Background: Malignant peripheral nerve sheath tumour (MPNST) is an aggressive orphan disease commonly affecting adolescents or young adults. Current knowledge of molecular tumour biology has been insufficient for development of rational trea
Externí odkaz:
https://doaj.org/article/120a8ea2f5d04915b737b8e0d970bebb
Autor:
Emanuela Palmerini, Giorgio Frega, Marco Gambarotti, Tommaso Frisoni, Marilena Cesari, Alberto Bazzocchi, Marco Miceli, Davide Maria Donati, Stefano Fanti, Cristina Nanni, Stefania Benini, Alessandra Longhi, Anna Paioli, Andrea Marrari, Rossella Hakim, Alberto Righi, Toni Ibrahim
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Background: Neurotrophic tyrosine receptor kinase (NTRK) gene-fusion targeted molecules revolutionized the paradigm of treatment of a limited subgroup of cancers of various histologies. Entrectinib and larotrectinib obtained unprecedented response ra
Externí odkaz:
https://doaj.org/article/65afba1c23ad453fa34d144e8c213b50
Autor:
Anna Maria Frezza, Silvia Stacchiotti, Frederic Chibon, Jean‐Michelle Coindre, Antoine Italiano, Cleofe Romagnosa, Silvia Bagué, Angelo Paolo Dei Tos, Luca Braglia, Emanuela Palmerini, Vittorio Quagliuolo, Javier Martin Broto, Antonio Lopez Pousa, Giovanni Grignani, Antonella Brunello, Jean‐Yves Blay, Robert Diaz Beveridge, Iwona Lugowska, Tom Lesluyes, Roberta Maestro, Franco Domenico Merlo, Paolo Giovanni Casali, Alessandro Gronchi
Publikováno v:
Cancer Medicine, Vol 12, Iss 2, Pp 1350-1357 (2023)
Abstract Background The Complexity INdex in SARComas (CINSARC) is a transcriptional signature derived from the expression of 67 genes involved in mitosis control and chromosome integrity. This study aims to assess CINSARC value of in an independent s
Externí odkaz:
https://doaj.org/article/c40f99d4dfaa49b68f9028cd3bb23f20
Autor:
David J. Barnes, Peter Dutton, Øyvind Bruland, Hans Gelderblom, Ade Faleti, Claudia Bühnemann, Annemiek van Maldegem, Hannah Johnson, Lisa Poulton, Sharon Love, Gesa Tiemeier, Els van Beelen, Karin Herbschleb, Caroline Haddon, Lucinda Billingham, Kevin Bradley, Stefano Ferrari, Emanuela Palmerini, Piero Picci, Uta Dirksen, Sandra J. Strauss, Pancras C. W. Hogendoorn, Emmeline Buddingh, Jean-Yves Blay, Anne Marie Cleton-Jansen, Andrew Bassim Hassan
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-14 (2022)
Abstract The phase III clinical study of adjuvant liposomal muramyl tripeptide (MTP-PE) in resected high-grade osteosarcoma (OS) documented positive results that have been translated into regulatory approval, supporting initial promise for innate imm
Externí odkaz:
https://doaj.org/article/ba7b4b2dbc0a4593a5504bba271da783
Autor:
Emanuela Palmerini, Roberta Sanfilippo, Giovanni Grignani, Angela Buonadonna, Antonella Romanini, Giuseppe Badalamenti, Virginia Ferraresi, Bruno Vincenzi, Alessandro Comandone, Antonio Pizzolorusso, Antonella Brunello, Fabio Gelsomino, Tommaso De Pas, Toni Ibrahim, Lorena Gurrieri, Federica Grosso, Francesca Zanelli, Maria Abbondanza Pantaleo, Laura Milesi, Libero Ciuffreda, Vittorio Ferrari, Emanuela Marchesi, Irene Quattrini, Alberto Righi, Elisabetta Setola, Elisa Carretta, Paolo G. Casali, Piero Picci, Stefano Ferrari
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundAmong sarcomas, which are rare cancers with an incidence of 24 months. Nine patients had at least one grade 3/4 adverse event, mostly being bone marrow toxicity (n=6).ConclusionsTrabectedin has some anti-tumor activity in some ultra-rare an
Externí odkaz:
https://doaj.org/article/30a46f7377b34eb8bf06a1773885869a
Autor:
Michiel Van De Sande, William D Tap, Heather L Gelhorn, Xin Ye, Rebecca M Speck, Emanuela Palmerini, Silvia Stacchiotti, Jayesh Desai, Andrew J Wagner, Thierry Alcindor, Kristen Ganjoo, Javier Martín-Broto, Qiang Wang, Dale Shuster, Hans Gelderblom, John H Healey
Publikováno v:
Acta Orthopaedica, Vol 92, Iss 4, Pp 493-499 (2021)
Background and purpose — The ENLIVEN trial showed that, after 25 weeks, pexidartinib statistically significantly reduced tumor size more than placebo in patients with symptomatic, advanced tenosynovial giant cell tumor (TGCT) for whom surgery was n
Externí odkaz:
https://doaj.org/article/7df2d1b97ecc4f04afde34eaa2472648